Finance Watch: 2021 Is Now Two Away From 100 Biopharma IPOs
Three Health Care-Focused SPACs Also Went Public
Executive Summary
Public Company Edition: Entrada’s initial public offering grossed $181.5m while Aura raised $75.6m and Biofrontera brought in $18m. Also, AnaptysBio received $250m in Jemperli royalty deal and 4D Molecular Therapeutics grossed $118.8m in a follow-on offering.
You may also be interested in...
Pipeline Watch: Phase III Readouts In Breast And Liver Cancer Plus COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Positive Signs For Valneva’s COVID-19 Vaccine, But Efficacy Data And Orders Still Lacking
Immunogenicity data from Valneva’s COV-COMPARE study are encouraging, but the inactivated vaccine will need proper efficacy data to gain a toehold in a crowded market.
IPO Update: Average Return Turns Negative For Newly Public Biopharma Firms
With 88 initial public offerings in the US through the end of the third quarter of 2021, the biopharma industry is two IPOs ahead of the full-year 2020 total, but with an average return of -4% momentum may slow.